Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.3555 -0.0049 (-1.36%)
Streaming Delayed Price Updated: 11:13 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Four Poster Presentations at the 2023 ACNP Annual Meeting
Via Investor Brand Network
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Topline Safety, Efficacy Data for MDD Study
Via Investor Brand Network
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing
Via Investor Brand Network
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event
Via Investor Brand Network
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
From Cybin Inc.
Via Business Wire
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
Via Investor Brand Network
Cybin Announces up to US$64 Million Offering of Units
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
Via Investor Brand Network
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
Via Investor Brand Network
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
From Cybin Inc.
Via Business Wire
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
Via Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.